tbuckley/cabot-search huggingface dataset:
722P Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial
Authors: L. Gladieff, J. Martinez-Garcia, M. Takekuma, G. Villacampa, U. De Giorgi, P. Harter, K. Hellman, L. Duska, A. Godoy Ortiz, C. Bellier, H. Nishio, M.J. Rubio Pérez, N. Delanoy, L. Fariñas Madrid, D. Berton, J.D. Alarcon, J.E. Kurtz, K. Nishino, L.M. Randall, A. Oaknin
Journal: Annals of Oncology (2024)
724P Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
Authors: G. Li, A. Huang, Y. Zhao, B. Li, Y. Ding, S. Lai, J. Zhang, H. Zhu, D. Li, Q. Li, X. Jia, Y. Qi, Y. Li, Y. Guo
Journal: Annals of Oncology (2024)
738P Global, phase Ib dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced (a) endometrial cancer (EC) that progressed on platinum-based chemotherapy (CTx) and an anti-PD-(L)1 immunotherapy (IO)
Authors: J-Y. Lee, K. Hasegawa, B-G. Kim, B.R. Corr, S. Kondo, S. Suzuki, M. Yunokawa, D.S. Miller, T. Tamai, L. Dutta, K. O'Hara, T. Sahara, V. Makker
Journal: Annals of Oncology (2024)
720MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study
Authors: J. Shu, T. Zhu, Y. Huang, Q. Xu, R. Guo, H. Liu, H. Zhao, L. Zhu, X. Wang, X. Xu, W. Cheng, J. Tang, Q. Zhu, X. Chen, R. An, J. Gao, G. Li, Z. Zhang, H. Zhou, Q. Zhou
Journal: Annals of Oncology (2024)
714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study
Authors: A. Oaknin, J.E. Ang, S.Y. Rha, K. Yonemori, R. Kristeleit, C-C. Lin, T. Satoh, P. Estevez Garcia, M.A.N. Sendur, L. Medina Rodríguez, A. Italiano, I. Lugowska, I.L. Ray-Coquard, A.M. Oza, J.L. Zhao, S. Gajavelli, J. Filant, S. Bodla, Y.Y. Janjigian, F. Meric-Bernstam
Journal: Annals of Oncology (2024)
709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Authors: D. Lorusso, Y. Xiang, K. Hasegawa, G. Scambia, M.H. Leiva Gálvez, P. Ramos Elias, A. Acevedo, M. Bednarikova, A.J.P.D.S. Gomes, F. Contreras Mejia, A. Reiss, F. Zagouri, J-Y. Lee, V. Saevets, A. Ayhan, P. Liu, K.U. Yamada, M. Puglisi, S. Pignata, L. Duska
Journal: Annals of Oncology (2024)
745P Biomarker-driven targeted therapy in platinum-resistant ovarian cancer (BRIGHT): An open-label, multicenter, umbrella trial
Authors: Q. Gao, H. Zhang, H. Zheng, R. An, J. Jiang, Q. Li, Z. Chen, J. Li, G. Li, R. Li, R. Xie, D. Ma
Journal: Annals of Oncology (2024)
736P Exceptional clinical benefit (ECB) from immune checkpoint inhibitors (ICIs) in mismatch-repair deficient (MMRd) in recurrent /metastatic endometrial cancer (r/mEC): Are we curing a subset of MMRd EC patients (pts)?
Authors: J.F. Grau Béjar, T. Guinel, R. Mazzeo, L. Musacchio, O. Le Saux, R. Sabatier, H. Salaun, L. Eberst, C. Garcia Duran, L. Carità, G. Villacampa, J-S. Frenel, G. Scambia, I. Ray-Coquard, D. Lorusso, A. Oaknin, A. Leary
Journal: Annals of Oncology (2024)
705P Subsequent malignant neoplasms (SMN) in patients with germ cell tumor of the testis (TGCT): Implications on a genetic vs stem cell origin of cancers
Authors: S. Vellanki, A.K. Trikannad Aswhini Kumar, A. Joon, N.M. Zacharias, M.R. Estecio, M.T. Campbell, J.F. Ward, L. Pisters, M. Zhang, A.C. Johns, D. Sanchez, S-M. Tu
Journal: Annals of Oncology (2024)
702P Survival and related factors in testicular non-seminomatous patients undergoing high-dose chemotherapy and autologous stem cell transplantation: Experience of Turkey's highest volume transplantation center
Authors: M.B. Aykan, I. Erturk, R. Acar, G.S.Y. Keskin, A.F. Kose, N. Karadurmus
Journal: Annals of Oncology (2024)
737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study
Authors: A. Danska-Bidzinska, V. Makker, V. Salutari, A. Ayhan, I. Romero, T. Levy, M. McCormack, J-F. Baurain, P. Mach, K.A. Cadoo, H. Mackay, M.L. Friedlander, A.D. Santin, B.M. Slomovitz, D.S. Miller, J. McKenzie, L. Yao, V. Khemka, A. Nogueira-Rodrigues, C. Marth
Journal: Annals of Oncology (2024)
734P Impact of investigator-assessed response on overall survival (OS) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Authors: C. Mathews, A. Koliadi, L. Gilbert, B.M. Slomovitz, F. Frühauf, B. Buttin, N. Özgül, B.J. Monk, G. Fountzilas, C. Billingsley, J. Trinidad, P. Braly, J. Boone, D. Black, S. Sharma, S.J. Lubinga, D.J. Sharpe, G. Ronzino, M.A. Powell, M.R. Mirza
Journal: Annals of Oncology (2024)
746P Phase III MIRASOL trial: Updated overall survival results of mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in patients (pts) with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression
Authors: L. Gardner Coffman, B. You, E.P. Hamilton, Y. Garcia Garcia, K.N. Moore, D. Sonnenburg, G. Scambia, S. Derio, J. Thomes Pepin, D. Klasa-Mazurkiewicz, J. Tromp, S. Breuer, S. Weroha, O. Sukhina, Y. Wang, J.J. Stec, T. Van Gorp
Journal: Annals of Oncology (2024)
721MO Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors
Authors: G.E. Konecny, A.E. Wahner Hendrickson, B. Winterhoff, A.A. Adjei, A. Kung, L-L. Miller, M.F. Press, I. Qazi, N. Scholler, H. Dokainish, S. Letrent, D. Slamon
Journal: Annals of Oncology (2024)
725P Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
Authors: D. Denschlag, F. Heitz, L.C. Fangmann, M. Kerkmann, P.H. Klecker, L. Woelber, P. Mach, A. Fink, D. Bokhua, N. de Gregorio, F. Hemptenmacher, V. Friebe, P. Wimberger, A. Jaeger, S. Mittelstadt, M. Kalder, W. Schröder, H. Bronger, P. Harter, B. Czogalla
Journal: Annals of Oncology (2024)
704P Characteristics and palliative management of patients with cisplatin-refractory germ cell tumours: A Global Germ Cell Cancer Collaborative Group (G3) retrospective registry study
Authors: C. Oing, C. Seidel, P. Giannatempo, A. Tryakin, U. De Giorgi, H. Sagstuen Haugnes, M. Hentrich, A. Dieing, S. Zschäbitz, J.A. Gietema, S.C. Fischer, C.D. Fankhauser, X. Garcia Del Muro, J. Aparicio, M. Ottaviano, M. Pichler, M. Brito Goncalves, P. Paffenholz, P. Rescigno, C. Bokemeyer
Journal: Annals of Oncology (2024)
712MO Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)
Authors: J.E. Kurtz, E. Pujade-Lauraine, A. Oaknin, L. Belin, C. Grimm, R. Kocian, H. Denys, O.S. Rosengarten, P. Follana, J. Sehouli, J. Martinez-Garcia, J. Alexandre, A-C. Hardy-Bessard, J-S. Frenel, R. Sabatier, L. Gladieff, T. De La Motte Rouge, N. Bonichon Lamichhane, E. Kalbacher, F. Heitz
Journal: Annals of Oncology (2024)
716MO Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer
Authors: J. Wang, R. An, Y. Huang, J. Zhang, J.C.H. Goh, K. Jiang, G. Yu, L. Chen, D.M. Provencher, Y. Tang, G. Li, H. Qiu, B. Akala, E. Chartash, Y. Zhou, X. Jin, J. Ge, X. Wu
Journal: Annals of Oncology (2024)
733P Efficacy and safety of sacituzumab govitecan (SG) in patients with advanced/metastatic endometrial cancer (EC): Updated results from TROPiCS-03
Authors: B.R. Corr, E.E. Dumbrava, A.I. Spira, L. Willmott, J.E. Butrynski, K.Y. Tse, J. Patel, S. Mekan, S. Mocci, T. Wu, A.D. Santin
Journal: Annals of Oncology (2024)
715MO Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study
Authors: D. Wang, K. Wang, R. An, G. Yu, K. Zhang, D. Wang, K. Jiang, Y. Gao, Y. Cheng, Y. Liu, H. Qiu, X. Wang, T. Liu, B. Akala, E. Chartash, Y. Li, X. Li, X. Jin, J. Ge, J. Li
Journal: Annals of Oncology (2024)
718MO Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FRα) expression: Results from the PICCOLO trial
Authors: A.A. Secord, B.R. Corr, S. Lewin, E. Diver, S-M. Ayuk, Y. Wang, C. Murphy, V. Salutari, A. Barquin Garcia, F. Galvez Montosa, I.L. Ray-Coquard, C. Mathews, G.E. Konecny, A. Oaknin, M.J. Rubio Pérez, A. Bonaventura, S. Pignata
Journal: Annals of Oncology (2024)
710MO Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial
Authors: G. Eminowicz, S. Vaja, D. Gallardo, C. Kent, M. Panades, A. Anand, M. Persic, J. Forrest, R. Bhana, M. Adusumalli, A. Chan, A.M. Hacker, A. Hackshaw, J.A. Ledermann, M. McCormack
Journal: Annals of Oncology (2024)
729P Patterns of survivorship care of cervical cancer patients with or without HIV infection in Botswana 2015-2022
Authors: S. Amoo-Mitchual, C. Kernell, J. George, S. Tuli, P. Patel, B.M. Monare, R. Ketlametswe, A. Seiphetlheng, G. Ramontshonyana, M. Kassick, L. Bazzett-Matabele, P. Vuylsteke, K. Rendle, S. Grover
Journal: Annals of Oncology (2024)
740P A monocentric analysis of ESCAT gene actionability detection in non-specific molecular profile (NSMP) early-stage endometrial cancer
Authors: L. Mastrantoni, F. Camarda, C. Nero, S. Duranti, I. Marino, R. Trozzi, V. Iacobelli, A. Minucci, F. Giacomini, G. Maneri, L. Giacò, C. Parrillo, M. Karimi, A. Preziosi, T. Pasciuto, F. Fanfani, G. Scambia
Journal: Annals of Oncology (2024)
713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial
Authors: O. Klein, M.S. Carlino, M. Michael, C.R. Underhill, J. So, D. Kee, Y. Antill, W-S. Lam, H. Chan, R.A. Harrup, A. Hamilton, J.B. Palmer, D.M. Thomas, K. Wilkie, J. Cebon, B. Gao
Journal: Annals of Oncology (2024)
698P Outcomes of patients with testicular germ cell tumors in Latin-America
Authors: S. Campos Gomez, I. Lyra-Gonzalez, N. Sobrevilla-Moreno, M.T. Bourlon de los Rios, R.A. Ramírez Fallas, M.G. Diaz Alvarado, M-I. Enríquez Aceves, J.A. Saenz Frias, S. Macias Diaz, F.E. Arreguin Gonzalez, L. Richter, R. Gomez-Martinez, N.A. Lopez-Facundo, J.E. Gonzales Nogales, E.F. Ortiz-de la O, A. Morales-Peralta, A. Reyes-Lopez, M. Ramos Ramirez, A. Mandujano-Romero, F.E. Vera-Badillo
Journal: Annals of Oncology (2024)
676TiP MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors
Authors: C. Lemech, G. Kichenadasse, C. Teng, A. Nagrial, G. Richardson, T.G. Humphries, A.J. Killen, A. Joshua, J.J. Liu, M. Churchill, M. Barnett, M. Cioffi, R. Cosman
Journal: Annals of Oncology (2024)
700P Detection of circulating tumor DNA and chromosome 3p25.3 gain in relapsed/refractory germ cell tumors and impact of salvage high-dose chemotherapy: Results from the Italian Germ Cell Cancer Group 04 study
Authors: U. De Giorgi, M. Polano, C. Menna, E. Scarpi, C. Gianni, G. Schepisi, G. Gurioli, C. Casadei, S. Bleve, A. Virga, P. Ulivi, D. Montanari, G. Rosti, G. Toffoli, M. Urbini
Journal: Annals of Oncology (2024)
711O Avelumab + methotrexate to eradicate low-risk gestational trophoblastic tumors in first-line setting: TROPHAMET phase I/II trial
Authors: B. You, J-P. Lotz, P. Descargues, F. Joly Lobbedez, T. De La Motte Rouge, C. Lebreton, L. Gladieff, P. Follana, M. Jamelot, J. Massardier, T. Hajri, M. Alves-Ferreira, S. Bin, C. Langlois-Jacques, M. Bonjour, A. Roux, C. Desauw, M. Provansal Gross, F. Golfier, P-A. Bolze
Journal: Annals of Oncology (2024)
743P Immunotherapy plus chemotherapy in the first-line treatment for primary advanced or recurrent endometrial cancer: An extracted individual patient data and trial-level meta-analysis
Authors: M.C. Gouveia, F. Lazar Neto, M. Trento, M.T. Cunha, M.R. Mirza, D. Lorusso, R. Colombo Bonadio, M. Scaranti
Journal: Annals of Oncology (2024)
653P A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 &amp; CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
Authors: M.C.H. Ng, W.P. Yong, F. Meric-Bernstam, R.W. Lentz, V. Srirangam, J.R. Cometa, S. Blanchard, R. Nellore, A. Tan, Y-A. Lee, J. Lim, S. Gan, C. Koh, Q. Adanan, J. Joy, V. Pendharkar, J.P.S. Yeong, V. Diermayr
Journal: Annals of Oncology (2024)
609O CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): A phase I study
Authors: R-H. Xu, D. Ruan, S. Luo, X. Liang, Z. Niu, Q. Dang, Z. Pan, Y. Zhang, X. Li, H. Li, X. Xiao, S. Cai, Y. Dong, J. Zhang, Z. Li, H. Lan, H. Lu, S. Wang, Q. Wu, J. Xie
Journal: Annals of Oncology (2024)
741P Comparison of the Idylla microsatellite instability (MSI) test with a gold standard MSI test and mismatch repair immunohistochemistry in endometrial cancer
Authors: R. Erber, I. Unser, J. Emons, P. Gass, M. Ruebner, M.W. Beckmann, P.A. Fasching, A. Hartmann, R. Stöhr
Journal: Annals of Oncology (2024)
657P Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
Authors: N. Herbel, K. Ouali, F-X. Danlos, C.P. Massard, V. Goldschmidt, J-M. Michot, A. Laparra, A. Bernard-Tessier, A. Gazzah, R. Bahleda, A. Hollebecque, C. Henon, S. Postel-Vinay, Y. Loriot, V. Ribrag, A. Marabelle, K. Fizazi, S. Ponce Aix, S. Champiat, C. Baldini
Journal: Annals of Oncology (2024)
661P Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial
Authors: B.J. Sikkema, S. Champiat, E.H. Gort, F-X. Danlos, V. Moreno Garcia, F. Opdam, H. Gelderblom, M. Chaney, L. Prestegarden, F.A. Eskens
Journal: Annals of Oncology (2024)
591P Cost-utility of systemic anticancer therapy (SACT) with or without metastasectomy including local ablative therapy (LAT) for metastatic colorectal cancer (mCRC) patients
Authors: J. Kontiainen, K.I. Lehtomaki, T.T. Muhonen, E. Heerva, A. Algars, R. Ristamaki, H. Stedt, A. Lamminmäki, R. Kallio, T. Salminen, E. Osterlund, S. Aho, M.T. Barlund, P. Halonen, L-M. Soveri, A. Nordin, A. Uutela, B. Glimelius, H. Isoniemi, P.J. Osterlund
Journal: Annals of Oncology (2024)
726P Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025
Authors: K. Hasegawa, D. Shintani, S. Suzuki, K. Oda, M. Yunokawa, K. Yonemori, M. Mori, A. Kurosaki, M. Mori, S. Kitano, A. Ogasawara, Y. Saigusa, H. Matsushita, T. Misumi
Journal: Annals of Oncology (2024)
701P Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT)
Authors: H. Ebrahimi, M. Shodiya, E. Maldonado, T. Othman, R. Barragan-Carrillo, X. Li, A. Rock, A. Tripathi, S.K. Pal, T.B. Dorff, A. Zhumkhawala, R. Tetens Hoeg, C. Oliai, R. Olin, M. Mei, A. Chehrazi-Raffle
Journal: Annals of Oncology (2024)
732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Authors: S.V. Blank, M. McCollum, C. Anderson, K. Pennington, E. Salinas, D.L. Richardson, B.M. Slomovitz, B-G. Kim, J. Liu, M. Mori, P.L. Ramos Guette, C. Joseph de Pádua, J. Martinez-Garcia, C. Papadimitriou, K. Grisan, R.L. Póka, M. Kowgier, P.M.D. Del Rosario, E. Van Nieuwenhuysen, S. Westin
Journal: Annals of Oncology (2024)
619MO Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)
Authors: B.A. Carneiro, E. Rosen, E. Fontana, E.K. Lee, N.B. Mettu, S. Lheureux, R. Plummer, I.M. Silverman, J.D. Schonhoft, J. Yang, G. Gomez, K. Fei, D. Ulanet, P.A. Basciano, T.A. Yap, M. Hoejgaard
Journal: Annals of Oncology (2024)
658P First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors
Authors: C. Fava Gaspar, J.C. Park, G.S. Falchook, R. Wesolowski, H. Soliman, P.A. Ott, M.A. Bilen, M. Mckean, V. Villaflor, L.Q.M. Chow, A. Yanez, C. Dupont, J. Shepherd, T. Cheema, J.M. Goldberg, I. Puzanov, A. Spreafico
Journal: Annals of Oncology (2024)
668P First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease
Authors: T. Marron, S. Rosen, D. Orr, J. Powderly, N. Khaskhely, L. Bonham, M. Nelson, C. Taromino, D. Taylor, J. Kumer, P. Ellmark, S. Fritzell, S.V. Ambarkhane, D. Huebner, A. Alahmadi
Journal: Annals of Oncology (2024)
695P Assessment of the utility of CT scans in the long-term follow-up of metastatic non-seminomatous germ cell tumours (mNSGCT): The Late CT study
Authors: D. Chakrabarti, M. Singhera, Z. Rajan, L. Satchwell, K. Jones, V. Bennett, E. Greenlay, M. Miletic, D. Raggi, A. Reid, A. Sohaib, R.A. Huddart
Journal: Annals of Oncology (2024)
735P HRD signature (HRDsig) in endometrial cancer (EC)
Authors: B. Pothuri, B. Decker, E.S. Sokol, D.I. Lin, N.A. Danziger, A.B. Schrock, J. Elvin, M.A. Levy, H. Tukachinsky
Journal: Annals of Oncology (2024)
707P Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study
Authors: E.R. Israelyan, A. Tryakin, A. Rumyantsev, M. Fedyanin, A. Tyulyandina, A. Klimov, V. Matveev, M.I. Volkova, A. Paychadze, Y. Bychkov, Y. Bychkov, G. Yunaev, A. Tsareva, T. Tikhomirova, A. Zorinova, S. Tjulandin
Journal: Annals of Oncology (2024)
719MO A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer
Authors: E.K. Lee, O. Yeku, I. Winer, E.P. Hamilton, D.L. Richardson, J. Zhang, G.E. Konecny, I.C. Anderson, X. Wu, D. Orr, S. Patel, A. Jewell, J. Wang, A.I. Spira, A. Melnyk, L. Seamon, E. Kavalerchik, Z. Chen, E. Song, J.A. Call
Journal: Annals of Oncology (2024)
747P SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC)
Authors: C.L. Scott, M.L. Friedlander, K. Francis, A.E.R. Kartikasari, K. Diamante, N. Bound, C. Davies, R. O’Connell, Y.C. Lee, J. Lombard, S.E. Baron-Hay, Y. Antill, C. Shannon, S. Selva-Nayagam, P.J. Beale, K. Shield-Artin, M. Wakefield, C. Vandenberg, M. Plebanski, C.K. Lee
Journal: Annals of Oncology (2024)
622P Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Authors: Z. Song, X. Li, Y. Liu, Y. Yuan, R. Lin, H. Shi, Y. Luo, T. Lv, Y. Zhang, L. Zhu, Y. Zhu, S. Xie, B. Zhang, Z. Wang
Journal: Annals of Oncology (2024)
683TiP A phase I study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: The NiraPim (EPOC2102) study
Authors: H. Nakajima, H. Kubota, K. Tsukamoto, T. Eiraku, K. Takahashi, K. Kobayashi, Y. Komatsu, H. Kotani, T. Kato, M. Wakabayashi, T. Fujisawa, Y. Nakamura, A. Ohashi, T. Yoshino, A. Sato, Y. Naito
Journal: Annals of Oncology (2024)
679TiP Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors
Authors: D. Sarker, N. Cook, C. Leung, B.Y. Aktas, R.C. Dawson, N. Demeris, P. Mozgunov, D. Howe, N. Austin, N. Swain, I.P. Leader, A. Manage, A. Azizi, G.W. Halbert, L. Brotherton, S. Svetlik, N.B. Westwood, D. Paisley, S.N. Symeonides, B. Basu
Journal: Annals of Oncology (2024)
621P Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Authors: Y. Honma, I. Kinoshita, C. Ishioka, K. Ishigaki, T. Enokida, H. Hayashi, S. Nishiwaki, N. Nishida, M. Muto, M. Tabata, M. Ito, R. Ko, K. Sunami, T. Shimoi, N. Yamamoto
Journal: Annals of Oncology (2024)
632P Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Authors: C-C. Lin, R. Schneider, M. Gutierrez, L. Shen, K. Chung, D.B. Doroshow, B. Gao, M. Millward, C-Y. Hsieh, C. Xu, S.X. Cai, Y.E. Tian, L. Liu, C. Shen, Y. Tan, Y. He, C. Zhang, L. Li, M. Ma, L. Xu
Journal: Annals of Oncology (2024)
610O Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6
Authors: M.R. Patel, E.P. Hamilton, S.A. Piha-Paul, J. Henry, U. Banerji, M.N. Al Hallak, H. Okada, M. Qian, X. Zhang, N. Said, V. Chatikhine, E. Fontana
Journal: Annals of Oncology (2024)
623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12
Authors: F.P. Lin, A. Mersiades, J. Lee, W. Xu, S. Chinchen, M. Charakidis, S. Thavaneswaran, B.G.M. Hughes, C.R. Underhill, H.S. Takhar, R. Harrup, A. Nagrial, M. Millward, J. Desai, D. Espinoza, C.K. Lee, B.J. Solomon, J. Simes, N. Pavlakis, D. Thomas
Journal: Annals of Oncology (2024)
649P Phase I study of SHR-A2102, a nectin-4 targeted ADC, in patients with advanced solid tumors
Authors: H. Zhong, R. Zhong, R. Qiao, Q. Lan, M. Yan, T. Zhang, K. Chen, J. Huang, H-M. Hong, G. Lin, X. Li, Y. Huang, L. Song
Journal: Annals of Oncology (2024)
680TiP A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
Authors: A.R. Minchom, K. Culm, E. Garmey, L. Makris, M.L. Johnson, D. Sommerhalder, E. Garralda, J. Henry, M. Yang, L. Mei, M.M. Cotreau, A-L. Goenaga, D. Burzyn, Z-Y. Yang, R. Wei, V. Chhaljani, J. Mascola, G. Nabel, E.E. Dumbrava
Journal: Annals of Oncology (2024)
744P A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296)
Authors: J-M. Lee, S. MacLaughlan, D. Matei, M. Song, L. Brubaker, B. Rimmel, R.N. Eskander, C. Kyi, H. Williams, L. Duska, F. Musa, R.L. Coleman, B.M. Slomovitz, E.C. Gamelin, J-M. Cuillerot, M.M. Phadnis, B. Guercio, S. Crafton, P. Konstantinopoulos
Journal: Annals of Oncology (2024)
696P Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma
Authors: D. Pfister, P. Paffenholz, F. Seelemeyer, S. Zschäbitz, M. Hentrich, P. Albers, Y. Che, S. Thy, A. Gerdtson, A. Kjellmann, H. Negaard, A. Ghoreifu, S. Daneshmand
Journal: Annals of Oncology (2024)
717MO SHR-A1921 in platinum-resistant ovarian cancer (PROC): data from a first-in-human (FIH) phase I study
Authors: Z. Song, L. Chen, Q. Dang, D. Tang, T. Liu, L. Wang, J. Wang, C. Liu, X. Qu, X. Li, J. Zhong, S. Zhang, N. Xing, Y. Li, Y. Wu, Z. Lin, Z. Zhang, S. Wang
Journal: Annals of Oncology (2024)
629P Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Authors: S. Fu, A.M. Tsimberidou, E.E. Dumbrava, Y. Yuan, S. McLeod, D. Karp, J. Rodon, H. Yu, J. Peng, L.M. Daniel, S.A. Piha-Paul, A. Naing, F. Meric-Bernstam
Journal: Annals of Oncology (2024)